Literatur
-
1
Lok A S, Heathcote E J, Hoofnagle J H.
Management of hepatitis B: 2000 - summary of a workshop.
Gastroenterology.
2001;
120 (7)
1828-1853 (Ia)
-
2
Niederau C, Heintges T, Lange S. et al .
Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.
N Engl J Med.
1996;
334 (22)
1422-1427 (IIa)
-
3
Craxi A, Di Bona D, Camma C.
Interferon alfa for HBeAg positive chronic hepatitis B: systemativ review.
J Hepatol.
2003;
39 (Suppl. 1)
99-105 (Ia)
-
4
Hoofnagle J H, Di Bisceglie A M.
The treatment of chronic viral hepatitis.
N Engl J Med.
1997;
336 (5)
347-356
-
5
Pastore G, Santantonio T, Monno L. et al .
Permanent inhibition of viral replication induced by low dosage of human leukocyte interferon in patients with chronic hepatitis B.
Hepatogastroenterology.
1988;
35 (2)
57-61 (Ib)
-
6
Fattovich G, Brollo L, Boscaro S. et al .
Long-term effect of low dose recombinant interferon therapy in patients with chronic hepatitis B.
J Hepatol.
1989;
9 (3)
331-337 (Ib)
-
7
Brook M G, Chan G, Yap I. et al .
Randomised controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection.
BMJ.
1989;
299 (6700)
652-656 (Ib)
-
8
Waked I, Amin M, Abd e F. et al .
Experience with interferon in chronic hepatitis B in Egypt.
J Chemother.
1990;
2 (5)
310-318 (II)
-
9
Lin S M, Sheen I S, Chien R N. et al .
Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection.
Hepatology.
1999;
29 (3)
971-975 (II)
-
10
Korenman J, Baker B, Waggoner J. et al .
Long-term remission of chronic hepatitis B after alfa-interferon therapy.
Ann Intern Med.
1991;
114 (8)
629-634 (III)
-
11
Hsu Y S, Chien R N, Yeh C T. et al .
Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.
Hepatology.
2002;
35 (6)
1522-1527 (III)
-
12
Lau D T, Everhart J, Kleiner D E. et al .
Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa.
Gastroenterology.
1997;
113 (5)
1660-1667 (Ib)
-
13
Krogsgaard K, Bindslev N, Christensen E. et al .
The treatment effect of alfa interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep).
J Hepatol.
1994;
21 (4)
646-655 (Ia)
-
14
Cooksley W G, Piratvisuth T, Wanf Y J. et al .
40Kd Peg-Interferon alfa 2A (Pegasys) efficacy and safety results, from a phase II, randomized actively controlled, multi-center study in the treatment of HBeAg positive chronic hepatitis B.
J Viral Hepat.
2003;
10
298-305 (Ib)
-
15
Dienstag J L, Schiff E R, Wright T L. et al .
Lamivudine as initial treatment for chronic hepatitis B in the United States.
N Engl J Med.
1999;
341 (17)
1256-1263 (Ib)
-
16
Lai C L, Chien R N, Leung N W. et al .
A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.
N Engl J Med.
1998;
339 (2)
61-68 (Ib)
-
17
Kweon Y O, Goodman Z D, Dienstag J L. et al .
Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B.
J Hepatol.
2001;
35 (6)
749-755 (II)
-
18
Dienstag J L, Goldin R D, Heathcote E J. et al .
Histological outcome during long-term lamivudine therapy.
Gastroenterology.
2003;
124 (1)
105-117 (Ib)
-
19
Dienstag J L, Schiff E R, Mitchell M. et al .
Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.
Hepatology.
1999;
30 (4)
1082-1087 (IIb)
-
20
Liaw Y F, Leung N W, Chang T T. et al .
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.
Gastroenterology.
2000;
119 (1)
172-180 (Ib)
-
21
Leung N W, Lai C L, Chang T T. et al .
Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
Hepatology.
2001;
33 (6)
1527-1532 (Ib)
-
22
Dienstag J L, Cianciara J, Karayalcin S. et al .
Durability of serologic response after lamivudine treatment of chronic hepatitis B.
Hepatology.
2003;
37 (4)
748-755 (IIa)
-
23
Honkoop P, de Man R A, Niesters H G. et al .
Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy.
Hepatology.
2000;
32 (3)
635-639 (III)
-
24
Peters M G, Singer G, Howard T. et al .
Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin.
Transplantation.
1999;
68 (12)
1912-1914 (III)
-
25
Lai C L, Dienstag J, Schiff E. et al .
Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.
Clin Infect Dis.
2003;
36 (6)
687-696 (III)
-
26
Lau D T, Khokhar M F, Doo E. et al .
Long-term therapy of chronic hepatitis B with lamivudine.
Hepatology.
2000;
32 (4 Pt 1)
828-834 (III)
-
27
Peters M, Schiff E, Benhamou Y. et al .
Adefovir dipivoxil (ADV) demonstrates anti-viral efficacy and clinical benefit in the treatment of lamivudine resistant (LAM-R) chronic HBV: An analysis of four clinical trials.
Gastroenterology.
2002;
123 (1)
69 (Ia)
-
28
Schiff E R, Lai C L, Hadziyannis S. et al .
Behalf of the Adefovir Dipovoxil Study 435 International Investigators Group. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients.
Hepatology.
2003;
38
1419-1427 (IIa)
-
29
Perrillo R P, Wright T, Rakela J. et al .
A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.
Hepatology.
2001;
33 (2)
424-432 (IIa)
-
30
Hann H W, Fontana R J, Wright T. et al .
A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis.
Liver Transpl.
2003;
9 (1)
49-56 (IIa)
-
31
Marcellin P, Chang T T, Lim S G. et al .
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
N Engl J Med.
2003;
348 (9)
808-816 (Ib)
-
32
Westland C, Yang H L, Delaney W. et al .
Resistance monitoring in two phase III clinical studies of adefovir dipivoxil for the treatment of chronic hepatitis B infection.
Hepatology.
2003;
38
96-103 (IIa)
-
33
Manns M P, Neuhaus P, Atkinson G F. et al .
Famciclovir treatment of hepatitis B infection following liver transplantation: a long-term, multi-centre study.
Transpl Infect Dis.
2001;
3 (1)
16-23 (IIa)
-
34
Wedemeyer H, Boker K H, Pethig K. et al .
Famciclovir treatment of chronic hepatitis B in heart transplant recipients: a prospective trial.
Transplantation.
1999;
68 (10)
1503-1511 (IIa)
-
35
Hadziyannis S J, Manesis E K, Papakonstantinou A.
Oral ganciclovir treatment in chronic hepatitis B virus infection: a pilot study.
J Hepatol.
1999;
31 (2)
210-214 (Ib)
-
36
Gish R G, Lau J Y, Brooks L. et al .
Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients.
Hepatology.
1996;
23 (1)
1-7 (III)
-
37
Bozkaya H, Yurdaydin C, Bozdayi A M. et al .
Oral ganciclovir for treatment of lamivudine-resistant hepatitis B virus infection: a pilot study.
Clin Infect Dis.
2002;
35 (8)
960-965 (IIa)
-
38
Van Bommel F, Schernick A, Hopf U. et al .
Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation.
Gastroenterology.
2003;
124 (2)
586-587 (III)
-
39
Benhamou Y, Tubiana R, Thibault V.
Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus.
N Engl J Med.
2003;
348 (2)
177-178 (III)
-
40
Van Bommel F, Wunsche T, Schurmann D. et al .
Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication.
Hepatology.
2002;
36 (2)
507-508 (III)
-
41
Schalm S W, Heathcote J, Cianciara J. et al .
Lamivudine and alfa interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial.
Gut.
2000;
46 (4)
562-568 (Ib)
-
42
Barbaro G, Zechini F, Pellicelli A M. et al .
Long-term efficacy of interferon alfa-2 b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial.
J Hepatol.
2001;
35 (3)
406-411 (Ib)
-
43
Schiff E R, Dienstag J L, Karayalcin S. et al .
Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders.
J Hepatol.
2003;
38 (6)
818-826 (Ib)
-
44
Santantonio T, Niro G A, Sinisi E. et al .
Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study.
J Hepatol.
2002;
36 (6)
799-804 (Ib)
-
45
Peters M, Hann H W, Martin P. et al .
Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses LAM-resistant hepatitis B virus (HBV) replication: 16 week interim analysis.
Gastroenterology.
2004;
126 (1)
91-101 (Ib)
-
46
Chan H L, Tang J L, Tam W. et al .
The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis.
Aliment Pharmacol Ther.
2001;
15 (12)
1899-1905 (Ia)
-
47
Mutchnick M G, Lindsay K L, Schiff E R. et al .
Thymosin alfa1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study.
J Viral Hepat.
1999;
6 (5)
397-403 (Ib)
-
48
Cotonat T, Quiroga J A, Lopez-Alcorocho J M. et al .
Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients.
Hepatology.
2000;
31 (2)
502-506 (IIa)
-
49
Dahmen A, Herzog-Hauff S, Bocher W O. et al .
Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B.
J Med Virol.
2002;
66 (4)
452-460 (IIa)
-
50
Heintges T, Petry W, Kaldewey M. et al .
Combination therapy of active HBsAg vaccination and interferon-alfa in interferon-alfa nonresponders with chronic hepatitis B.
Dig Dis Sci.
2001;
46 (4)
901-906 (IIa)
-
51
Carreno V, Zeuzem S, Hopf U. et al .
A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B.
J Hepatol.
2000;
32 (2)
317-324 (Ib)
-
52
Cohard M, Poynard T, Mathurin P. et al .
Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect metaanalysis.
Hepatology.
1994;
20 (6)
1390-1398 (Ia)
-
53
Zarski J P, Causse X, Cohard M. et al .
A randomized, controlled trial of interferon alfa-2 b alone and with simultaneous prednisone for the treatment of chronic hepatitis B. French Multicenter Group.
J Hepatol.
1994;
20 (6)
735-741 (Ib)
-
54
Krogsgaard K.
Does corticosteroid pretreatment enhance the effect of alfa interferon treatment in chronic hepatitis B?.
J Hepatol.
1994;
20 (2)
159-162 (IV)
-
55
Perrillo R P.
Chronic hepatitis B: problem patients (including patients with decompensated disease).
J Hepatol.
1995;
22 (1 Suppl.)
45-48 (Ia)
Prof. Dr. med. Michael P. Manns
Direktor der Abteilung für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover
Carl-Neuberg-Str. 1
30625 Hannover
eMail: Manns.Michael@mh-hannover.de
